Clinical Trial Update: GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma [Phase 2]

View source ↗

Summary

Clinical trial update describing the use of the GAD-M regimen as first-line therapy in untreated Extranodal NK/T-cell lymphoma, nasal type (Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Nk T-cell Lymphoma Nasal Type

Drugs mentioned

• GAD-M regimen

Snippet

Sponsor: Sun Yat-sen University | Conditions: Extranodal NK/T-cell Lymphoma, Nasal Type | Phase 2 | Status: UNKNOWN